← Leaderboards
Michael R Waarts
Sloan-Kettering Inst Can Research
$177,608
Attributed
$177,608
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $83.9K · FY2021–23$100K$75K$50K$25K$0
'21
'22
'23
Funding mix
By agency
NIH$177,608 · 2
By mechanism
F99$95,946 · 1
F31$81,662 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Ross L Levine$31,715,816
- Scott W Lowe$63,222,126
- Omar Abdel-Wahab$18,758,829
- Eirini Papapetrou$13,419,805
- Michael Kharas$18,485,709
Others in their field
Other Emerging Leaders on “Laboratories”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$463,311,620
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$210,784,687
- Lynn Briscoe · Leidos Biomedical Research, Inc.$172,823,180
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedmand · Leidos Biomedical Research, Inc.$105,458,370
Research focus
LaboratoriesPhenotypeEpigenetic ProcessHematopoiesisMouse ModelMutationCrispr ScreenDnmt3aFitnessGenetic VariantMemorial Sloan-Kettering Cancer CenterMolecularCareer DevelopmentMutantCellsAnticancer ResearchDependenceClonal ExpansionAcute Myelocytic LeukemiaEventGene FrequencyGeneticMalignant - DescriptorPrevent
Grant awards (4)
Identification of therapeutic targets in clonal hematopoiesis$47,694
F99 · FY2023 · CA · contact PI
Identification of therapeutic targets in clonal hematopoiesis$48,252
F99 · FY2022 · CA · contact PI
Investigating the Role of DNMT3A mutations in the initiation and maintenance of myeloid malignancies$35,626
F31 · FY2022 · CA · contact PI
Investigating the Role of DNMT3A mutations in the initiation and maintenance of myeloid malignancies$46,036
F31 · FY2021 · CA · contact PI